TokenPost·
Analysts Highlight Obesity Drugs and Sales Growth in Pharma Picks
35%
Dupixent sales rise
Lilly’s tirzepatide and retatrutide featured alongside Gilead’s 6.8% revenue growth and a 35% rise in Sanofi’s Dupixent sales.
More news
- TokenPostSolflare Launches Private Mode With Support From Helius
- Bitcoin.com NewsCoinone Data Breach Exposes Passwords and Sensitive Customer Records
- TokenPostNovo Nordisk Reports New CagriSema Weight-Loss and Function Findings
- TokenPostLuxor Pledges Full Payment for Hashrate Redirected Through Commander
- TokenPostDiamondback Nears Acquisition of Double Eagle V for About $5 Billion
- TokenPostAlien Worlds’ TLM Rises 11.66% in an Hour to $0.001015